DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder

Information source: Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Panic Disorders

Intervention: VENLAFAXINE (Drug); Paroxetine (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Wyeth is now a wholly owned subsidiary of Pfizer

Official(s) and/or principal investigator(s):
Trial Manager, Study Director, Affiliation: Pfizer CT.gov Call Center

Summary

The purpose of this pilot study is to evaluate the improvement in social function following therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine. An additional purpose of this pilot study is to obtain the tolerability of using venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine.

Clinical Details

Official title: Pilot Study of Venlafaxine Extended Release (XR) in the Treatment of Panic Disorder (PD) in Comparison to Paroxetine.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To evaluate the improvement of social function following therapy with Venlafaxine extended release (XR)in the Treatment of Panic Disorder in comparison to Paroxetine.

Secondary outcome: Obtain the tolerability of using Venlafaxine extended release (XR) in the treatment of Panic Disorder in comparison to Paroxetine.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Meet DSM IV criteria for Panic Disorder (with or without agoraphobia) for at least 3

months before study day 1.

- Have a minimum of 8 full-symptom panic attacks during the 4 weeks before the

screening visit.

- Provide a written informed consent

Exclusion Criteria:

- Treatment with Venlafaxine within 6 months of study day 1, as well Paroxetine

- Known hypersensitivity to Venlafaxine or related compounds as well to Paroxetine.

- Psychopharmacologic drugs within 14 days of study day 1

Locations and Contacts

Sao Paulo 04038-031, Brazil

Sao Paulo 04829-000, Brazil

Jundiai, Sao Paulo, Brazil

Santo Andre, Sao Paulo 09290-610, Brazil

Additional Information

Starting date: January 2005
Last updated: April 1, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015